# SIRS Therapeutics UG

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sirs-therapeutics

- Industry: Biotechnology
- Headquarters: Munich, Germany
- Latest round: Seed (Apr 15, 2020)
- Investors on record: 1

## About

Founded in 2020 and based in Munich, Germany, SIRS Therapeutics UG develops and provides FX06, a 28 amino acid peptide from human fibrin that reduces leukocyte extravasation and preserves the endothelial barrier. The company focuses to treat patients with Respiratory Distress Syndrome(ARDS), Systemic Inflammatory Response Syndrome(SIRS), and COVID-19 patients.

## Funding rounds

- Seed, Apr 15, 2020 — Wellington Partners

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Seed